MCID: BRN035
MIFTS: 51

Brain Stem Glioma

Categories: Bone diseases, Cancer diseases, Neuronal diseases

Aliases & Classifications for Brain Stem Glioma

MalaCards integrated aliases for Brain Stem Glioma:

Name: Brain Stem Glioma 12 15 17
Brainstem Neuroglial Tumor 12
Glioma of Brainstem 71
Brainstem Glioma 6

Classifications:



External Ids:

Disease Ontology 12 DOID:4202
NCIt 49 C8501
UMLS 71 C0677865

Summaries for Brain Stem Glioma

Disease Ontology : 12 A brain stem cancer that is characterized by mass lesion of the brainstem, associated cranial nerve nuclei and long tracts, has material basis in abnormally proliferating cells, derives from glial cells.

MalaCards based summary : Brain Stem Glioma, also known as brainstem neuroglial tumor, is related to adult brain stem glioma and diffuse intrinsic pontine glioma. An important gene associated with Brain Stem Glioma is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Methotrexate and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and spinal cord, and related phenotypes are Decreased substrate adherent cell growth and Decreased substrate adherent cell growth

Wikipedia : 74 A brainstem glioma is a cancerous glioma tumor in the brainstem. Around 75% are diagnosed in children... more...

Related Diseases for Brain Stem Glioma

Diseases in the Brain Stem Glioma family:

Adult Brain Stem Glioma

Diseases related to Brain Stem Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 241)
# Related Disease Score Top Affiliating Genes
1 adult brain stem glioma 34.7 IDH2 IDH1 H3-3B H3-3A BSG
2 diffuse intrinsic pontine glioma 33.3 H3C2 H3C1 H3-3B H3-3A
3 glioma 31.4 TP53 PIK3CA IDH2 IDH1 H3C11 H3C1
4 oligodendroglioma 31.0 TP53 IDH2 IDH1 FGFR1 EGFR
5 juvenile pilocytic astrocytoma 30.9 IDH1 H3-3B H3-3A
6 high-grade astrocytoma 30.9 IDH1 ACVR1
7 grade iii astrocytoma 30.8 TP53 KDM4C IDH2 IDH1 H3-3B H3-3A
8 mixed glioma 30.7 TP53 IDH2 IDH1 EGFR
9 ganglioglioma 30.6 TP53 KDM4C H3-3A BRAF
10 supratentorial cancer 30.6 TP53 IDH2 IDH1 H3-3B EGFR
11 gliomatosis cerebri 30.6 TP53 KDM4C IDH1 EGFR BRAF
12 brain cancer 30.4 TP53 PIK3CA KDM4C IDH2 IDH1 EGFR
13 gliosarcoma 30.4 TP53 IDH2 IDH1 H3-3B H3-3A FGFR1
14 medulloblastoma 30.3 TP53 PIK3CA KDM4C IDH1 H3C1 FGFR1
15 glioma susceptibility 1 30.2 TP53 PIK3CA IDH2 IDH1 H3C1 H3-3A
16 brain stem cancer 29.7 KDM4C H3C6 H3C4 H3C3 H3C2 H3C12
17 glioblastoma multiforme 29.7 TP53 PIK3CA IDH2 IDH1 H3C6 H3C4
18 fibrillary astrocytoma 29.7 TP53 KDM4C IDH2 IDH1 H3C6 H3C4
19 childhood brain stem glioma 12.8
20 brain stem astrocytic neoplasm 11.3
21 brain stem ependymoma 11.3
22 glial tumor 10.8
23 enchondroma 10.7 IDH2 IDH1
24 rare head and neck tumor 10.7 TP53 PIK3CA
25 nevus of ota 10.7 TP53 BRAF
26 frontal lobe neoplasm 10.7 TP53 IDH1 EGFR
27 breast duct papilloma 10.7 IDH2 IDH1
28 esophageal basaloid squamous cell carcinoma 10.7 TP53 EGFR
29 cytogenetically normal acute myeloid leukemia 10.7 IDH2 IDH1
30 intracranial chondrosarcoma 10.7 IDH2 IDH1
31 vulvar disease 10.7 TP53 PIK3CA EGFR
32 central nervous system rhabdomyosarcoma 10.7 IDH2 IDH1
33 undifferentiated pleomorphic sarcoma 10.7 PIK3CA IDH2 IDH1
34 esophagus verrucous carcinoma 10.7 TP53 EGFR
35 breast hemangioma 10.7 TP53 IDH2 IDH1
36 hyperplastic polyposis syndrome 10.7 TP53 BRAF
37 breast squamous cell carcinoma 10.7 TP53 PIK3CA
38 gemistocytic astrocytoma 10.7 TP53 IDH2 IDH1
39 periosteal chondrosarcoma 10.7 IDH2 IDH1
40 thyroid carcinoma 10.7 TP53 PIK3CA BRAF
41 uterine body mixed cancer 10.7 TP53 PIK3CA EGFR
42 cerebellum cancer 10.7 TP53 IDH2 IDH1
43 anus cancer 10.7 TP53 PIK3CA EGFR
44 thyroid gland anaplastic carcinoma 10.7 TP53 PIK3CA BRAF
45 intraductal breast neoplasm 10.7 TP53 IDH2 IDH1
46 juxtacortical chondroma 10.7 KDM4C IDH2 IDH1
47 juvenile astrocytoma 10.7 TP53 IDH1 BRAF
48 cerebral ventricle cancer 10.7 TP53 IDH2 IDH1
49 gallbladder adenocarcinoma 10.7 TP53 PIK3CA EGFR
50 bone giant cell sarcoma 10.7 TP53 H3-3B H3-3A

Graphical network of the top 20 diseases related to Brain Stem Glioma:



Diseases related to Brain Stem Glioma

Symptoms & Phenotypes for Brain Stem Glioma

GenomeRNAi Phenotypes related to Brain Stem Glioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.43 ACVR1
2 Decreased substrate adherent cell growth GR00193-A-3 9.43 ACVR1 BRAF
3 Decreased substrate adherent cell growth GR00193-A-4 9.43 ACVR1 BRAF FGFR1
4 Increased cell migration GR00055-A-3 8.92 ACVR1 BRAF EGFR PIK3CA

MGI Mouse Phenotypes related to Brain Stem Glioma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.17 ACVR1 BRAF EGFR IDH2 KDM4C PIK3CA

Drugs & Therapeutics for Brain Stem Glioma

Drugs for Brain Stem Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 265)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
2
leucovorin Approved Phase 3 58-05-9 6006 143
3
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
4
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
5
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
6
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
7
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
8
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
9
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
10
Donepezil Approved Phase 3 120014-06-4 3152
11
Thioguanine Approved Phase 3 154-42-7 2723601
12
Ondansetron Approved Phase 3 99614-02-5 4595
13
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
14
Vorinostat Approved, Investigational Phase 2, Phase 3 149647-78-9 5311
15
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
16
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
17
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
18
Histamine Approved, Investigational Phase 3 51-45-6 774
19
Cyproheptadine Approved Phase 3 129-03-3 2913
20
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
21 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
22 Anti-Inflammatory Agents Phase 3
23 Antirheumatic Agents Phase 3
24 Vitamin B Complex Phase 3
25 Folic Acid Antagonists Phase 3
26 Vitamin B9 Phase 3
27 Folate Phase 3
28 glucocorticoids Phase 3
29 Analgesics Phase 3
30 Antimetabolites Phase 3
31 BB 1101 Phase 3
32 Antibodies, Monoclonal Phase 2, Phase 3
33 Liver Extracts Phase 3
34 Central Nervous System Depressants Phase 3
35 Nootropic Agents Phase 3
36 Cholinergic Agents Phase 3
37 Cholinesterase Inhibitors Phase 3
38 Mitogens Phase 2, Phase 3
39 Autonomic Agents Phase 3
40 Emetics Phase 3
41 Antiemetics Phase 3
42 Endothelial Growth Factors Phase 2, Phase 3
43 Immunoglobulin G Phase 2, Phase 3
44 Histone Deacetylase Inhibitors Phase 2, Phase 3
45 Cola Phase 3
46 Narcotics Phase 3
47 Anesthetics Phase 3
48 Anesthetics, General Phase 3
49 Analgesics, Opioid Phase 3
50 Adjuvants, Anesthesia Phase 3

Interventional clinical trials:

(show top 50) (show all 163)
# Name Status NCT ID Phase Drugs
1 Prospective Randomized Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Pediatric Diffuse Brainstem Glioma Unknown status NCT01878266 Phase 3
2 Treatment of Children and Adolescents With Diffuse Intrinsic Pontine Glioma and High Grade Glioma Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
3 Prospective Randomized Trial of Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children. Completed NCT01635140 Phase 3
4 Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old Completed NCT00002944 Phase 3 carboplatin;lomustine;procarbazine hydrochloride;thioguanine;vincristine sulfate
5 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
6 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
7 A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas Completed NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
8 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
9 A Controlled, Study of the Effect of Combination Antineoplaston Therapy [Atengenal (A10) and Astugenal (AS2-1)] on the QT/QTc Interval In Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem Glioma Not yet recruiting NCT02864888 Phase 3 Atengenal;Astugenal
10 A Randomized Phase 3 Study of Combination Antineoplaston Therapy [Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal)] Plus Radiation Therapy vs. Radiation Therapy Only in Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem Glioma Not yet recruiting NCT02887040 Phase 3 Atengenal;Astugenal
11 A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
12 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
13 Treatment of Children With Newly Diagnosed Diffuse Pontine Gliomas Using Conventional Radiotherapy and High Dose Tamoxifen Unknown status NCT00024336 Phase 2 tamoxifen citrate
14 A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
15 A Phase II Multi-Centre Study of Concomitant and Prolonged Adjuvant Temozolomide With Radiotherapy in Diffuse Pontine Gliomas Unknown status NCT00514397 Phase 2 motexafin gadolinium;temozolomide
16 Management of Children Aged Less Than 3 Years With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
17 A Phase 2 Study of Valproic Acid and Radiation, Followed by Maintenance Valproic Acid and Bevacizumab in Children With Newly Diagnosed High-grade Gliomas or Brainstem Gliomas Unknown status NCT00879437 Phase 2 Valproic acid;Bevacizumab
18 Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI) Unknown status NCT02819479 Phase 2 25% Mannitol;Low-dose Intra-arterial Bevacizumab
19 A Phase II Study of R115777 (Zarnestra) (NSC # 702818, IND# 58,359) in Children With Recurrent or Progressive: High Grade Glioma, Medulloblastoma/PNET or Brainstem Glioma Completed NCT00070525 Phase 2 tipifarnib
20 A Phase II Trial of Rebeccamycin Analogue (NSC #655649) in Children With Solid Tumors Completed NCT00006102 Phase 2 becatecarin
21 Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Brain Stem Glioma Completed NCT00003459 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
22 Phase I/II Trial of Gefitinib and Radiation in Pediatric Patients Newly Diagnosed With Brain Stem Tumors or Incompletely Resected Supratentorial Malignant Gliomas With Phase II Limited to Brain Stem Tumors Completed NCT00042991 Phase 1, Phase 2 gefitinib
23 Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma Completed NCT00179881 Phase 2 Carboplatin;Thalomid
24 Phase II Treatment of Adults and Children With Progressive Low Grade Gliomas With Temodal Completed NCT00003466 Phase 2 temozolomide
25 PHASE II STUDY OF CARBOPLATIN (CBDCA) IN THE TREATMENT OF CHILDREN AND ADULTS WITH PROGRESSIVE LOW GRADE GLIOMAS Completed NCT00002749 Phase 2 carboplatin
26 Phase II Study of Phenylacetate in Pediatric Patients With Central Nervous System Tumors Completed NCT00003241 Phase 2 phenylacetate
27 A Phase II Study of Motexafin-Gadolinium (NSC 695238, IND #55583) and Involved Field Radiation Therapy for Intrinsic Pontine Glioma of Childhood Completed NCT00387790 Phase 2 motexafin gadolinium
28 A Phase II Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas Completed NCT01118377 Phase 2 Capecitabine
29 Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms Completed NCT00004688 Phase 2 carmustine;mercaptopurine;streptozocin
30 Use of Nimotuzumab and Radiotherapy in the Treatment of Pediatric Patients With Diffuse Intrinsic Brainstem Glioma Completed NCT01145170 Phase 2
31 A Phase II Study of Temozolomide in the Treatment of Children With High Grade Glioma Completed NCT00028795 Phase 2 temozolomide
32 Treatment of Newly Diagnosed High-Grade Gliomas in Patients Ages Greater Than or Equal to 3 and Less Than or Equal to 21 Years With a Phase II Irinotecan Window Followed by Radiation Therapy and Temozolomide Completed NCT00004068 Phase 2 irinotecan hydrochloride;temozolomide
33 A TRIAL OF INTENSIVE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL RECONSTITUTION FOR PATIENTS BETWEEN SIX AND SIXTY YEARS OF AGE, WITH NON-PROGRESSIVE GLIOBLASTOMA MULTIFORME OR DIFFUSE INTRINSIC BRAINSTEM TUMORS, FOLLOWING INITIAL LOCAL-FIELD IRRADIATION Completed NCT00002619 Phase 2 carboplatin;thiotepa
34 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
35 A Phase II Trial of Continuous Low-Dose Temozolomide for Patients With Recurrent Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
36 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
37 Phase II Treatment of Adults With Recurrent Supratentorial Low Grade Glioma With Gliadel Wafers Completed NCT00003467 Phase 2 carmustine;polifeprosan 20 with carmustine implant
38 A PHASE II STUDY OF DOCETAXEL (TAXOTERE) (NSC# 628503) IN CHILDREN WITH RECURRENT SOLID TUMORS Completed NCT00002825 Phase 2 docetaxel
39 Phase II Trial Of High Dose Cyclophosphamide, Cisplatin And Carmustine With Stem Cell Reconstitution Followed By Specific Cellular Therapy In Patients With Recurrent Or Refractory Brain Tumors Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
40 Phase I/II Trial of R115777 and XRT in Pediatric Patients With Newly Diagnosed Non-Disseminated Intrinsic Diffuse Brainstem Gliomas Completed NCT00079339 Phase 1, Phase 2 tipifarnib
41 A Phase I/II Trial of Temodar in Pediatric Patients and Young Adults With High-Risk or Recurrent Solid Tumors Completed NCT00005952 Phase 1, Phase 2 temozolomide
42 A Phase II Trial Of Talampanel In Patients With Recurrent High-Grade Gliomas Completed NCT00064363 Phase 2 talampanel
43 Phase II Study of Antineoplastons A10 and AS2-1 in Children With Brain Tumors Completed NCT00003458 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
44 A Phase II Trial of Irinotecan in Recurrent Glioma Completed NCT00003134 Phase 2 irinotecan hydrochloride
45 Levetiracetam and Pregabalin for Monotherapy in Patients With Brain Tumors and Seizures. A Phase II Randomized Study. Completed NCT00629889 Phase 2 levetiracetam;pregabalin
46 Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Brain Tumors. Completed NCT00003457 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
47 A Pilot Study of Tamoxifen, Carboplatin and Topotecan in the Treatment of Recurrent or Refractory Primary Brain or Spinal Cord Tumors or Metastatic Epithelial Cancers With Central Nervous System Metastases Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
48 A Phase II Trial of O6-Benzylguanine and Temozolomide in Pediatric Patients With Recurrent or Progressive High-Grade Gliomas and Recurrent or Progressive Brainstem Tumors Completed NCT00275002 Phase 2 O6-benzylguanine;temozolomide
49 Donepezil and EGb761 in Improving Neurocognitive Function in Patients Who Have Previously Undergone Radiation Therapy for Primary Brain Tumor or Brain Metastases Completed NCT00070161 Phase 2 donepezil hydrochloride
50 Phase II Treatment of Children With Newly Diagnosed Malignant Central Nervous System Tumors With Temozolomide Prior to Radiation Therapy Completed NCT00005955 Phase 2 temozolomide

Search NIH Clinical Center for Brain Stem Glioma

Genetic Tests for Brain Stem Glioma

Anatomical Context for Brain Stem Glioma

MalaCards organs/tissues related to Brain Stem Glioma:

40
Brain, Breast, Spinal Cord, Lung, Thyroid, Bone, T Cells

Publications for Brain Stem Glioma

Articles related to Brain Stem Glioma:

(show top 50) (show all 175)
# Title Authors PMID Year
1
(Doctor…My child keeps falling over) unexpected MRI findings in children with history of frequent falls and dizziness: a case series. 61
31272995 2019
2
IDH1 Mutation in Brain Stem Glioma: Case Report and Review of Literature. 61
29682047 2018
3
Spontaneous complete regression of a brain stem glioma pathologically diagnosed as a high-grade glioma. 61
28808781 2017
4
Survival rates and prognostic predictors of high grade brain stem gliomas in childhood: a systematic review and meta-analysis. 61
28681244 2017
5
The Role of telovelar approach in fourth ventricular surgery: a new perspective. 61
29044454 2017
6
A Case of Primary Central Nervous System Lymphoma Located at Brain Stem in a Child. 61
27867930 2016
7
[Brain stem glioma: a rare cause of central vertigo in adults]. 61
28292097 2016
8
Clinical profile and outcomes in brainstem glioma: An institutional experience. 61
26425160 2015
9
Torticollis in children: an alert symptom not to be turned away. 61
26043711 2015
10
Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study. 61
25930724 2015
11
Comparison of Direct Side-to-End and End-to-End Hypoglossal-Facial Anastomosis for Facial Nerve Repair. 61
25819525 2015
12
Comment to the paper "The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brain stem glioma" by Burzynski et al. 61
25142686 2014
13
Clinicopathological features and treatment outcomes of brain stem gliomas in Saudi population. 61
25493242 2014
14
Brain stem glioma with spinal cord involvement in a young with neurofibromatosis type 1. 61
24614250 2014
15
[Blepharospasm as the presenting symptom of a brain stem glioma]. 61
24570363 2014
16
Exploratory evaluation of MR permeability with 18F-FDG PET mapping in pediatric brain tumors: a report from the Pediatric Brain Tumor Consortium. 61
23801675 2013
17
Progressive adult primary glioblastoma in the medulla oblongata with an unmethylated MGMT promoter and without an IDH mutation. 61
23053494 2013
18
[Diagnostic value of brain biopsy in a pediatric multiple sclerosis mimicking brain stem glioma]. 61
23812076 2013
19
Paediatric intra-axial posterior fossa tumours: pictorial review. 61
22977284 2013
20
Intracranial syphilitic gumma mimicking a brain stem glioma. 61
22723064 2012
21
Treatment of progressive brain stem glioma with bevacizumab: radiological, metabolic and histopathological aspects. 61
22048887 2012
22
Shall we treat hydrocephalus associated to brain stem glioma in children? 61
21928037 2011
23
Hydrocephalus in patients with neurofibromatosis type 1: MR imaging findings and the outcome of endoscopic third ventriculostomy. 61
21330395 2011
24
Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium. 61
21233173 2011
25
A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study. 61
20658614 2010
26
DTI fiber tracking to differentiate demyelinating diseases from diffuse brain stem glioma. 61
20363335 2010
27
Interstitial infusion of glioma-targeted recombinant immunotoxin 8H9scFv-PE38. 61
20371725 2010
28
Diffuse brain stem glioma. 61
20212241 2010
29
Imaging and clinical features of an intra-axial brain stem schwannoma. 61
19833800 2010
30
[Diffuse intrinsic brain stem glioma in children: current treatment and future directions]. 61
20018494 2010
31
Clinical experience with nimotuzumab in cuban pediatric patients with brain tumors, 2005 to 2007. 61
21483304 2009
32
Commentary on diffuse brain stem glioma in children. 61
19016114 2008
33
Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. 61
18324354 2008
34
Diagnostic and therapeutic challenges owing to concurrent pontine glioma and acute lymphoblastic leukemia. 61
18525463 2008
35
Citrate in pediatric CNS tumors? 61
18272551 2008
36
Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children's Oncology Group phase II study. 61
17278121 2008
37
Brain stem glioma, a rare cause of hearing loss and dysequilibrium. 61
21063295 2008
38
HSV encephalitis in a child with brain stem glioma: a rare complication of therapy. Case report and review of the neurosurgical literature. 61
17593375 2007
39
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. 61
17705175 2007
40
Somatostatin-receptor positive brain stem glioma visualized by octreoscan. 61
17627256 2007
41
Treatment of newly diagnosed diffuse brain stem gliomas in children: in search of the holy grail. 61
17492930 2007
42
Establishment of experimental glioma models at the intrinsic brainstem region of the rats. 61
17427273 2007
43
Paediatric brain-stem gliomas: MRI, FDG-PET and histological grading correlation. 61
16847598 2006
44
Primary midbrain cystic germinoma mimicking glioma: a case with neuroendoscopic biopsy. 61
16557347 2006
45
Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas. 61
16047359 2006
46
Temozolomide in resistant or relapsed pediatric solid tumors. 61
16047361 2006
47
Quality of health information on the Internet in pediatric neuro-oncology. 61
16533758 2006
48
ACTH deficiency in childhood cancer survivors. 61
15700255 2005
49
Hemifacial spasm caused by pontine glioma: case report and review of the literature. 61
16001287 2005
50
Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies. 61
16136028 2005

Variations for Brain Stem Glioma

ClinVar genetic disease variations for Brain Stem Glioma:

6 (show top 50) (show all 80) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 IDH1 NM_005896.3(IDH1):c.395G>A (p.Arg132His)SNV Pathogenic 156444 rs121913500 2:209113112-209113112 2:208248388-208248388
2 FGFR1 NM_023110.2(FGFR1):c.1638C>A (p.Asn546Lys)SNV Pathogenic 224896 rs779707422 8:38274849-38274849 8:38417331-38417331
3 TP53 NM_000546.5(TP53):c.517G>A (p.Val173Met)SNV Pathogenic 233951 rs876660754 17:7578413-7578413 17:7675095-7675095
4 TP53 NM_000546.5(TP53):c.742C>T (p.Arg248Trp)SNV Pathogenic 12347 rs121912651 17:7577539-7577539 17:7674221-7674221
5 TP53 NM_000546.5(TP53):c.733G>T (p.Gly245Cys)SNV Pathogenic 12349 rs28934575 17:7577548-7577548 17:7674230-7674230
6 TP53 NM_000546.5(TP53):c.733G>A (p.Gly245Ser)SNV Pathogenic 12365 rs28934575 17:7577548-7577548 17:7674230-7674230
7 TP53 NM_000546.5(TP53):c.818G>A (p.Arg273His)SNV Pathogenic 12366 rs28934576 17:7577120-7577120 17:7673802-7673802
8 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg)SNV Pathogenic 13652 rs121913279 3:178952085-178952085 3:179234297-179234297
9 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu)SNV Pathogenic 13653 rs121913279 3:178952085-178952085 3:179234297-179234297
10 TP53 NM_000546.5(TP53):c.743G>A (p.Arg248Gln)SNV Pathogenic 12356 rs11540652 17:7577538-7577538 17:7674220-7674220
11 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala)SNV Pathogenic 13659 rs121913274 3:178936092-178936092 3:179218304-179218304
12 BRAF NM_004333.6(BRAF):c.1799T>A (p.Val600Glu)SNV Pathogenic 13961 rs113488022 7:140453136-140453136 7:140753336-140753336
13 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr)SNV Pathogenic 39705 rs121913281 3:178952084-178952084 3:179234296-179234296
14 TP53 NM_000546.5(TP53):c.488A>G (p.Tyr163Cys)SNV Pathogenic 127814 rs148924904 17:7578442-7578442 17:7675124-7675124
15 TP53 NM_000546.5(TP53):c.743G>T (p.Arg248Leu)SNV Pathogenic 230253 rs11540652 17:7577538-7577538 17:7674220-7674220
16 PIK3CA NM_006218.4(PIK3CA):c.2176G>A (p.Glu726Lys)SNV Pathogenic 376476 rs867262025 3:178938934-178938934 3:179221146-179221146
17 TP53 NM_000546.5(TP53):c.578A>C (p.His193Pro)SNV Pathogenic 376612 rs786201838 17:7578271-7578271 17:7674953-7674953
18 TP53 NM_000546.5(TP53):c.818G>T (p.Arg273Leu)SNV Pathogenic 376655 rs28934576 17:7577120-7577120 17:7673802-7673802
19 TP53 NM_000546.5(TP53):c.517G>T (p.Val173Leu)SNV Pathogenic 376668 rs876660754 17:7578413-7578413 17:7675095-7675095
20 TP53 NM_000546.5(TP53):c.817C>A (p.Arg273Ser)SNV Pathogenic/Likely pathogenic 376656 rs121913343 17:7577121-7577121 17:7673803-7673803
21 IDH1 NM_005896.3(IDH1):c.395G>T (p.Arg132Leu)SNV Pathogenic/Likely pathogenic 375889 rs121913500 2:209113112-209113112 2:208248388-208248388
22 TP53 NM_000546.5(TP53):c.523C>G (p.Arg175Gly)SNV Pathogenic/Likely pathogenic 376649 rs138729528 17:7578407-7578407 17:7675089-7675089
23 IDH1 NM_005896.3(IDH1):c.394C>G (p.Arg132Gly)SNV Pathogenic/Likely pathogenic 375892 rs121913499 2:209113113-209113113 2:208248389-208248389
24 IDH1 NM_005896.3(IDH1):c.394C>A (p.Arg132Ser)SNV Pathogenic/Likely pathogenic 375893 rs121913499 2:209113113-209113113 2:208248389-208248389
25 PIK3CA NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln)SNV Pathogenic/Likely pathogenic,drug response 375896 rs104886003 3:178936091-178936091 3:179218303-179218303
26 IDH2 NM_001289910.1(IDH2):c.359G>T (p.Arg120Met)SNV Pathogenic/Likely pathogenic 375986 rs121913503 15:90631838-90631838 15:90088606-90088606
27 IDH2 NM_001289910.1(IDH2):c.359G>A (p.Arg120Lys)SNV Pathogenic/Likely pathogenic 375987 rs121913503 15:90631838-90631838 15:90088606-90088606
28 PIK3CA NM_006218.4(PIK3CA):c.1635G>T (p.Glu545Asp)SNV Pathogenic/Likely pathogenic 217293 rs121913275 3:178936093-178936093 3:179218305-179218305
29 TP53 NM_000546.5(TP53):c.818G>C (p.Arg273Pro)SNV Pathogenic/Likely pathogenic 231060 rs28934576 17:7577120-7577120 17:7673802-7673802
30 ACVR1 NM_001105.5(ACVR1):c.983G>A (p.Gly328Glu)SNV Pathogenic/Likely pathogenic 29595 rs387906589 2:158622516-158622516 2:157766004-157766004
31 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys)SNV Pathogenic/Likely pathogenic 13655 rs104886003 3:178936091-178936091 3:179218303-179218303
32 PIK3CA NM_006218.4(PIK3CA):c.1634A>G (p.Glu545Gly)SNV Pathogenic/Likely pathogenic 13656 rs121913274 3:178936092-178936092 3:179218304-179218304
33 TP53 NM_000546.5(TP53):c.734G>A (p.Gly245Asp)SNV Pathogenic/Likely pathogenic 12355 rs121912656 17:7577547-7577547 17:7674229-7674229
34 TP53 NM_000546.5(TP53):c.722C>G (p.Ser241Cys)SNV Likely pathogenic 177791 rs28934573 17:7577559-7577559 17:7674241-7674241
35 ACVR1 NM_001105.5(ACVR1):c.772A>G (p.Arg258Gly)SNV Likely pathogenic 216885 rs863224846 2:158626898-158626898 2:157770386-157770386
36 TP53 NM_000546.5(TP53):c.578A>G (p.His193Arg)SNV Likely pathogenic 184979 rs786201838 17:7578271-7578271 17:7674953-7674953
37 TP53 NM_000546.5(TP53):c.487T>G (p.Tyr163Asp)SNV Likely pathogenic 187052 rs786203436 17:7578443-7578443 17:7675125-7675125
38 TP53 NM_000546.5(TP53):c.722C>T (p.Ser241Phe)SNV Likely pathogenic 12359 rs28934573 17:7577559-7577559 17:7674241-7674241
39 TP53 NM_000546.5(TP53):c.577C>T (p.His193Tyr)SNV Likely pathogenic 230256 rs876658468 17:7578272-7578272 17:7674954-7674954
40 TP53 NM_000546.5(TP53):c.743G>C (p.Arg248Pro)SNV Likely pathogenic 237954 rs11540652 17:7577538-7577538 17:7674220-7674220
41 TP53 NM_000546.5(TP53):c.742C>G (p.Arg248Gly)SNV Likely pathogenic 376652 rs121912651 17:7577539-7577539 17:7674221-7674221
42 IDH1 NM_005896.3(IDH1):c.394C>T (p.Arg132Cys)SNV Likely pathogenic 375891 rs121913499 2:209113113-209113113 2:208248389-208248389
43 TP53 NM_000546.5(TP53):c.722C>A (p.Ser241Tyr)SNV Likely pathogenic 376663 rs28934573 17:7577559-7577559 17:7674241-7674241
44 TP53 NM_000546.5(TP53):c.721T>C (p.Ser241Pro)SNV Likely pathogenic 376664 rs1057520002 17:7577560-7577560 17:7674242-7674242
45 TP53 NM_000546.5(TP53):c.721T>G (p.Ser241Ala)SNV Likely pathogenic 376665 rs1057520002 17:7577560-7577560 17:7674242-7674242
46 TP53 NM_000546.5(TP53):c.373A>C (p.Thr125Pro)SNV Likely pathogenic 376666 rs1057520003 17:7579314-7579314 17:7675996-7675996
47 TP53 NM_000546.5(TP53):c.518T>A (p.Val173Glu)SNV Likely pathogenic 376669 rs1057519747 17:7578412-7578412 17:7675094-7675094
48 TP53 NM_000546.5(TP53):c.734G>C (p.Gly245Ala)SNV Likely pathogenic 265357 rs121912656 17:7577547-7577547 17:7674229-7674229
49 TP53 NM_000546.5(TP53):c.487T>C (p.Tyr163His)SNV Likely pathogenic 376680 rs786203436 17:7578443-7578443 17:7675125-7675125
50 TP53 NM_000546.5(TP53):c.577C>G (p.His193Asp)SNV Likely pathogenic 376613 rs876658468 17:7578272-7578272 17:7674954-7674954

Expression for Brain Stem Glioma

Search GEO for disease gene expression data for Brain Stem Glioma.

Pathways for Brain Stem Glioma

Pathways related to Brain Stem Glioma according to GeneCards Suite gene sharing:

(show all 44)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.22 TP53 PIK3CA KDM4C H3C6 H3C4 H3C3
2
Show member pathways
14.06 TP53 PIK3CA IDH1 H3C6 H3C4 H3C3
3
Show member pathways
13.91 TP53 H3C6 H3C4 H3C3 H3C2 H3C12
4
Show member pathways
13.89 TP53 H3C6 H3C4 H3C3 H3C2 H3C12
5
Show member pathways
13.84 TP53 H3C6 H3C4 H3C3 H3C2 H3C12
6
Show member pathways
13.82 KDM4C H3C6 H3C4 H3C3 H3C2 H3C12
7
Show member pathways
13.81 TP53 H3C6 H3C4 H3C3 H3C2 H3C12
8
Show member pathways
13.64 H3C6 H3C4 H3C3 H3C2 H3C12 H3C11
9
Show member pathways
13.57 PIK3CA H3C6 H3C4 H3C3 H3C2 H3C12
10
Show member pathways
13.57 TP53 PIK3CA H3C6 H3C4 H3C3 H3C2
11
Show member pathways
13.51 TP53 H3C6 H3C4 H3C3 H3C2 H3C12
12
Show member pathways
13.45 TP53 PIK3CA H3C6 H3C4 H3C3 H3C2
13
Show member pathways
13.39 TP53 PIK3CA H3C6 H3C4 H3C3 H3C2
14
Show member pathways
13.26 TP53 H3C6 H3C4 H3C3 H3C2 H3C12
15
Show member pathways
13.14 H3C6 H3C4 H3C3 H3C2 H3C12 H3C11
16
Show member pathways
13.14 KDM4C H3C6 H3C4 H3C3 H3C2 H3C12
17
Show member pathways
13.1 KDM4C H3C6 H3C4 H3C3 H3C2 H3C12
18
Show member pathways
13.02 H3C6 H3C4 H3C3 H3C2 H3C12 H3C11
19
Show member pathways
12.84 TP53 PIK3CA FGFR1 EGFR BRAF
20 12.81 TP53 PIK3CA FGFR1 EGFR BRAF
21
Show member pathways
12.8 H3C6 H3C4 H3C3 H3C2 H3C12 H3C11
22
Show member pathways
12.74 TP53 PIK3CA FGFR1 EGFR BRAF
23
Show member pathways
12.67 TP53 PIK3CA FGFR1 EGFR BRAF
24
Show member pathways
12.6 H3C6 H3C4 H3C3 H3C2 H3C12 H3C11
25
Show member pathways
12.52 TP53 PIK3CA FGFR1 EGFR BRAF
26
Show member pathways
12.48 TP53 PIK3CA EGFR BRAF
27
Show member pathways
12.47 TP53 PIK3CA FGFR1 EGFR ACVR1
28
Show member pathways
12.41 H3C6 H3C4 H3C3 H3C2 H3C12 H3C11
29 12.35 TP53 PIK3CA FGFR1 EGFR BRAF
30 12.27 TP53 H3C6 H3C4 H3C3 H3C2 H3C12
31
Show member pathways
12.24 TP53 PIK3CA FGFR1 EGFR BRAF
32
Show member pathways
12.18 TP53 PIK3CA BRAF ACVR1
33
Show member pathways
12.17 H3C6 H3C4 H3C3 H3C2 H3C12 H3C11
34 12.09 TP53 H3C6 H3C4 H3C3 H3C2 H3C12
35
Show member pathways
12.05 TP53 PIK3CA EGFR BRAF
36 11.85 TP53 PIK3CA IDH1 FGFR1 EGFR
37
Show member pathways
11.83 TP53 H3C6 H3C4 H3C3 H3C2 H3C12
38 11.81 TP53 PIK3CA H3C6 H3C4 H3C3 H3C2
39
Show member pathways
11.78 PIK3CA FGFR1 BRAF
40 11.72 TP53 EGFR BRAF
41 11.48 FGFR1 EGFR BRAF
42 11.42 H3C6 H3C4 H3C3 H3C2 H3C12 H3C11
43 11.25 PIK3CA EGFR BRAF
44
Show member pathways
10.8 IDH2 IDH1

GO Terms for Brain Stem Glioma

Cellular components related to Brain Stem Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 10.33 TP53 KDM4C H3C6 H3C4 H3C3 H3C2
2 extracellular region GO:0005576 10.22 IDH1 H3C6 H3C4 H3C3 H3C2 H3C12
3 nucleoplasm GO:0005654 10.21 TP53 KDM4C H3C6 H3C4 H3C3 H3C2
4 extracellular exosome GO:0070062 10.18 IDH2 IDH1 H3C6 H3C4 H3C3 H3C2
5 protein-containing complex GO:0032991 10.03 TP53 H3C6 H3C4 H3C3 H3C2 H3C12
6 chromosome GO:0005694 10.02 H3C6 H3C4 H3C3 H3C2 H3C12 H3C11
7 nuclear nucleosome GO:0000788 9.85 H3C6 H3C4 H3C3 H3C2 H3C12 H3C11
8 nucleosome GO:0000786 9.65 H3C6 H3C4 H3C3 H3C2 H3C12 H3C11
9 Barr body GO:0001740 9.48 H3-3B H3-3A
10 nuclear chromosome GO:0000228 9.32 H3C6 H3C4 H3C3 H3C2 H3C12 H3C11

Biological processes related to Brain Stem Glioma according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 10.21 H3C6 H3C4 H3C3 H3C2 H3C12 H3C11
2 blood coagulation GO:0007596 10.19 H3C6 H3C4 H3C3 H3C2 H3C12 H3C11
3 chromatin organization GO:0006325 10.18 KDM4C H3C6 H3C4 H3C3 H3C2 H3C12
4 regulation of gene silencing GO:0060968 10.08 H3C6 H3C4 H3C3 H3C2 H3C12 H3C11
5 regulation of gene silencing by miRNA GO:0060964 10.07 H3C6 H3C4 H3C3 H3C2 H3C12 H3C11
6 protein heterotetramerization GO:0051290 10.06 H3C6 H3C4 H3C3 H3C2 H3C12 H3C11
7 interleukin-7-mediated signaling pathway GO:0038111 10.03 H3C6 H3C4 H3C3 H3C2 H3C12 H3C11
8 negative regulation of gene expression, epigenetic GO:0045814 10.02 H3C6 H3C4 H3C3 H3C2 H3C12 H3C11
9 DNA replication-dependent nucleosome assembly GO:0006335 10.01 H3C6 H3C4 H3C3 H3C2 H3C12 H3C11
10 regulation of megakaryocyte differentiation GO:0045652 9.96 H3C6 H3C4 H3C3 H3C2 H3C12 H3C11
11 cell proliferation GO:0008283 9.91 TP53 H3-3B H3-3A EGFR
12 regulation of cell proliferation GO:0042127 9.9 TP53 FGFR1 EGFR BRAF
13 telomere organization GO:0032200 9.85 H3C6 H3C4 H3C3 H3C2 H3C12 H3C11
14 multicellular organism growth GO:0035264 9.82 TP53 H3-3B H3-3A
15 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.81 PIK3CA EGFR BRAF
16 positive regulation of cell growth GO:0030307 9.81 H3-3B H3-3A EGFR
17 cellular response to drug GO:0035690 9.78 TP53 EGFR BRAF
18 embryo implantation GO:0007566 9.75 H3-3B H3-3A BSG
19 nucleosome assembly GO:0006334 9.65 H3C6 H3C4 H3C3 H3C2 H3C12 H3C11
20 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.63 TP53 EGFR
21 salivary gland morphogenesis GO:0007435 9.62 FGFR1 EGFR
22 NADP metabolic process GO:0006739 9.62 IDH2 IDH1
23 isocitrate metabolic process GO:0006102 9.59 IDH2 IDH1
24 pericentric heterochromatin assembly GO:0031508 9.58 H3-3B H3-3A
25 regulation of centromere complex assembly GO:0090230 9.57 H3-3B H3-3A
26 negative regulation of chromosome condensation GO:1902340 9.56 H3-3B H3-3A
27 telomeric heterochromatin assembly GO:0031509 9.55 H3-3B H3-3A
28 glyoxylate cycle GO:0006097 9.54 IDH2 IDH1
29 chromatin silencing at rDNA GO:0000183 9.32 H3C6 H3C4 H3C3 H3C2 H3C12 H3C11

Molecular functions related to Brain Stem Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.9 TP53 H3C6 H3C4 H3C3 H3C2 H3C12
2 cadherin binding GO:0045296 9.73 IDH1 H3C6 H3C4 H3C3 H3C2 H3C12
3 protein heterodimerization activity GO:0046982 9.44 TP53 H3C6 H3C4 H3C3 H3C2 H3C12
4 isocitrate dehydrogenase (NADP+) activity GO:0004450 9.32 IDH2 IDH1
5 isocitrate dehydrogenase activity GO:0004448 9.26 IDH2 IDH1

Sources for Brain Stem Glioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....